While most of the strategies to target the IGF1/IGF1R so far have shown no or limited efficacy in the clinic, combining IGF1R inhibitors with anticancer immunotherapeutic or other targeted immunomodulatory drugs will certainly be a valuable strategy to overcome or prevent immunosupression and improve the treatment of patients affected by cancer. This evidence concerns the gene IGF1 and cancer.